Pulse Biosciences (PLSE) EBIT Margin (2021 - 2025)

Pulse Biosciences' EBIT Margin history runs 3 years deep, the most recent figure standing at 23682.56% for Q3 2025.

• In Q3 2025, EBIT Margin changed N/A year-over-year to 23682.56%; the TTM figure through Sep 2025 stood at 91798.84% (changed N/A YoY), while the FY2022 annual figure was 8293.86%, down 384999.0% from the prior year.
• EBIT Margin was 23682.56% for Q3 2025 at Pulse Biosciences, down from 97166.67% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 97166.67% in Q4 2022 to a low of 23682.56% in Q3 2025.
• Historically, EBIT Margin has averaged 10101.67% across 3 years, with a median of 3188.45% in 2022.
• Biggest YoY gain for EBIT Margin was 9899250 bps in 2022; the steepest drop was 9899250 bps in 2022.
• A 3-year view of EBIT Margin shows it stood at 1825.83% in 2021, then surged by 5422 bps to 97166.67% in 2022, then slumped by 124 bps to 23682.56% in 2025.
• The last three EBIT Margin figures came in at 23682.56% (Q3 2025), 97166.67% (Q4 2022), and 4671.33% (Q2 2022), per Business Quant data.